{"pmid":32414716,"title":"Drive-through testing in COVID-19: experience from NHS Lothian.","text":["Drive-through testing in COVID-19: experience from NHS Lothian.","The growing epidemic of SARS-CoV-2 challenges healthcare resources globally and mandates innovation. We describe our novel drive-through coronavirus testing which we used for testing of possible cases in the contain phase of UK response and are now using for healthcare worker testing. We found that this system was pragmatic, cost-efficient and favourable for patients. It is easily modifiable for use in future infectious disease outbreaks.","Clin Med (Lond)","Hill, Katherine","Campbell, Robyn","Mutch, Callum","Koch, Oliver","Mackintosh, Claire","32414716"],"abstract":["The growing epidemic of SARS-CoV-2 challenges healthcare resources globally and mandates innovation. We describe our novel drive-through coronavirus testing which we used for testing of possible cases in the contain phase of UK response and are now using for healthcare worker testing. We found that this system was pragmatic, cost-efficient and favourable for patients. It is easily modifiable for use in future infectious disease outbreaks."],"journal":"Clin Med (Lond)","authors":["Hill, Katherine","Campbell, Robyn","Mutch, Callum","Koch, Oliver","Mackintosh, Claire"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32414716","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.7861/clinmed.2020-0160","keywords":["covid-19","sars-cov-2","health economics","innovation","testing"],"locations":["GBR","NHS Lothian"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1666991242647437313,"score":9.490897,"similar":[{"pmid":32357977,"title":"Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic.","text":["Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic.","Rheumatology teams care for patients with diverse, systemic autoimmune diseases who are often immunosuppressed and at high risk of infections. The current COVID-19 pandemic has presented particular challenges in caring for and managing this patient group. The office of the chief medical officer (CMO) for England contacted the rheumatology community to provide expert advice on the identification of extremely vulnerable patients at very high risk during the COVID-19 pandemic who should be 'shielded'. This involves the patients being asked to strictly self-isolate for at least 12 weeks with additional funded support provided for them to remain at home. A group of rheumatologists (the authors) have devised a pragmatic guide to identifying the very highest risk group using a rapidly developed scoring system which went live simultaneous with the Government announcement on shielding and was cascaded to all rheumatologists working in England.","Clin Med (Lond)","Price, Elizabeth","MacPhie, Elizabeth","Kay, Lesley","Lanyon, Peter","Griffiths, Bridget","Holroyd, Christopher","Abhishek, Abhishek","Youngstein, Taryn","Bailey, Kathryn","Clinch, Jacqui","Shaikh, Muddassir","Rivett, Ali","32357977"],"abstract":["Rheumatology teams care for patients with diverse, systemic autoimmune diseases who are often immunosuppressed and at high risk of infections. The current COVID-19 pandemic has presented particular challenges in caring for and managing this patient group. The office of the chief medical officer (CMO) for England contacted the rheumatology community to provide expert advice on the identification of extremely vulnerable patients at very high risk during the COVID-19 pandemic who should be 'shielded'. This involves the patients being asked to strictly self-isolate for at least 12 weeks with additional funded support provided for them to remain at home. A group of rheumatologists (the authors) have devised a pragmatic guide to identifying the very highest risk group using a rapidly developed scoring system which went live simultaneous with the Government announcement on shielding and was cascaded to all rheumatologists working in England."],"journal":"Clin Med (Lond)","authors":["Price, Elizabeth","MacPhie, Elizabeth","Kay, Lesley","Lanyon, Peter","Griffiths, Bridget","Holroyd, Christopher","Abhishek, Abhishek","Youngstein, Taryn","Bailey, Kathryn","Clinch, Jacqui","Shaikh, Muddassir","Rivett, Ali"],"date":"2020-05-03T11:00:00Z","year":2020,"_id":"32357977","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.7861/clinmed.2020-0160","keywords":["covid-19","sars-cov-2","health economics","innovation","testing"],"locations":["GBR","GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1666138495342608387,"score":168.78413},{"pmid":32371418,"title":"Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic.","text":["Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic.","Rheumatology teams care for patients with diverse, systemic autoimmune diseases who are often immunosuppressed and at high risk of infections. The current COVID-19 pandemic has presented particular challenges in caring for and managing this patient group. The office of the chief medical officer (CMO) for England contacted the rheumatology community to provide expert advice on the identification of extremely vulnerable patients at very high risk during the COVID-19 pandemic who should be 'shielded'. This involves the patients being asked to strictly self-isolate for at least 12 weeks with additional funded support provided for them to remain at home. A group of rheumatologists (the authors) have devised a pragmatic guide to identifying the very highest risk group using a rapidly developed scoring system which went live simultaneous with the Government announcement on shielding and was cascaded to all rheumatologists working in England.","Clin Med (Lond)","Price, Elizabeth","MacPhie, Elizabeth","Kay, Lesley","Lanyon, Peter","Griffiths, Bridget","Holroyd, Christopher","Abhishek, Abhishek","Youngstein, Taryn","Bailey, Kathryn","Clinch, Jacqui","Shaikh, Muddassir","Rivett, Ali","32371418"],"abstract":["Rheumatology teams care for patients with diverse, systemic autoimmune diseases who are often immunosuppressed and at high risk of infections. The current COVID-19 pandemic has presented particular challenges in caring for and managing this patient group. The office of the chief medical officer (CMO) for England contacted the rheumatology community to provide expert advice on the identification of extremely vulnerable patients at very high risk during the COVID-19 pandemic who should be 'shielded'. This involves the patients being asked to strictly self-isolate for at least 12 weeks with additional funded support provided for them to remain at home. A group of rheumatologists (the authors) have devised a pragmatic guide to identifying the very highest risk group using a rapidly developed scoring system which went live simultaneous with the Government announcement on shielding and was cascaded to all rheumatologists working in England."],"journal":"Clin Med (Lond)","authors":["Price, Elizabeth","MacPhie, Elizabeth","Kay, Lesley","Lanyon, Peter","Griffiths, Bridget","Holroyd, Christopher","Abhishek, Abhishek","Youngstein, Taryn","Bailey, Kathryn","Clinch, Jacqui","Shaikh, Muddassir","Rivett, Ali"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32371418","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.7861/clinmed.2020-0149","keywords":["covid-19","sars-cov-2","health economics","innovation","testing"],"locations":["GBR","GBR"],"countries":["United Kingdom"],"countries_codes":["GBR|United Kingdom"],"topics":["Prevention"],"weight":1,"_version_":1666138496444661762,"score":168.78413},{"pmid":32389405,"title":"Understanding Antibody Testing for COVID-19.","text":["Understanding Antibody Testing for COVID-19.","The orthopedic community has seen the COVID-19 pandemic decimate elective surgical volumes in most geographies. Patients and essential workers, such as health care providers, remain rightfully concerned about how to appropriately begin to return to work and community activity in a safe and responsible manner. Many believe that testing for the presence of antibodies on a widespread scale could help drive evidence-based decision-making, both on an individual and societal scale. Much information, and an equal amount of misinformation, has been produced on antibody testing. Education about the role and science of such testing is critically important for programs to be effectively understood and managed.","J Arthroplasty","Jacofsky, David","Jacofsky, Emilia M","Jacofsky, Marc","32389405"],"abstract":["The orthopedic community has seen the COVID-19 pandemic decimate elective surgical volumes in most geographies. Patients and essential workers, such as health care providers, remain rightfully concerned about how to appropriately begin to return to work and community activity in a safe and responsible manner. Many believe that testing for the presence of antibodies on a widespread scale could help drive evidence-based decision-making, both on an individual and societal scale. Much information, and an equal amount of misinformation, has been produced on antibody testing. Education about the role and science of such testing is critically important for programs to be effectively understood and managed."],"journal":"J Arthroplasty","authors":["Jacofsky, David","Jacofsky, Emilia M","Jacofsky, Marc"],"date":"2020-05-12T11:00:00Z","year":2020,"_id":"32389405","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.arth.2020.04.055","keywords":["covid","covid-19","pcr","antibodies","antibody","coronavirus","screening","testing"],"topics":["Prevention"],"weight":1,"_version_":1666528580216029184,"score":106.325386},{"pmid":32375201,"title":"'All In': A Pragmatic Framework for COVID-19 Testing and Action on a Global Scale.","text":["'All In': A Pragmatic Framework for COVID-19 Testing and Action on a Global Scale.","Current demand for SARS-CoV-2 testing is straining material resource and labor capacity around the globe. As a result, the public health and clinical community are hindered in their ability to monitor and contain the spread of COVID-19. Despite broad consensus that more testing is needed, pragmatic guidance towards realizing this objective has been limited. This paper addresses this limitation by proposing a novel and geographically agnostic framework (the 4Ps Framework) to guide multidisciplinary, scalable, resource-efficient, and achievable efforts towards enhanced testing capacity. The 4Ps (Prioritize, Propagate, Partition, and Provide) are described in terms of specific opportunities to enhance the volume, diversity, characterization, and implementation of SARS-CoV-2 testing to benefit public health. Coordinated deployment of the strategic and tactical recommendations described in this framework have the potential to rapidly expand available testing capacity, improve public health decision-making in response to the COVID-19 pandemic, and/or to be applied in future emergent disease outbreaks.","EMBO Mol Med","Pettit, S D","Jerome, K R","Rouquie, D","Mari, B","Barbry, P","Kanda, Y","Matsumoto, M","Hester, S","Wehmas, L","Botten, J W","Bruce, E A","32375201"],"abstract":["Current demand for SARS-CoV-2 testing is straining material resource and labor capacity around the globe. As a result, the public health and clinical community are hindered in their ability to monitor and contain the spread of COVID-19. Despite broad consensus that more testing is needed, pragmatic guidance towards realizing this objective has been limited. This paper addresses this limitation by proposing a novel and geographically agnostic framework (the 4Ps Framework) to guide multidisciplinary, scalable, resource-efficient, and achievable efforts towards enhanced testing capacity. The 4Ps (Prioritize, Propagate, Partition, and Provide) are described in terms of specific opportunities to enhance the volume, diversity, characterization, and implementation of SARS-CoV-2 testing to benefit public health. Coordinated deployment of the strategic and tactical recommendations described in this framework have the potential to rapidly expand available testing capacity, improve public health decision-making in response to the COVID-19 pandemic, and/or to be applied in future emergent disease outbreaks."],"journal":"EMBO Mol Med","authors":["Pettit, S D","Jerome, K R","Rouquie, D","Mari, B","Barbry, P","Kanda, Y","Matsumoto, M","Hester, S","Wehmas, L","Botten, J W","Bruce, E A"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32375201","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.15252/emmm.202012634","topics":["Prevention"],"weight":1,"_version_":1666138496377552896,"score":106.20599},{"pmid":32295659,"pmcid":"PMC7180327","title":"Drawing on Israel's Experience Organizing Volunteers to Operationalize Drive-Through Coronavirus Testing Centers.","text":["Drawing on Israel's Experience Organizing Volunteers to Operationalize Drive-Through Coronavirus Testing Centers.","To increase the country's capacity to test and track suspected coronavirus disease 2019 (COVID-19) cases, Israel launched drive-through testing centers in key cities, including Tel Aviv, Jerusalem, Be'er Sheva, and Haifa. This article examines the challenges that the national emergency medical services and volunteers faced in the process of implementing drive-through testing centers to offer lessons learned and direction to health-care professionals in other countries.","Disaster Med Public Health Prep","Kim, Edward","32295659"],"abstract":["To increase the country's capacity to test and track suspected coronavirus disease 2019 (COVID-19) cases, Israel launched drive-through testing centers in key cities, including Tel Aviv, Jerusalem, Be'er Sheva, and Haifa. This article examines the challenges that the national emergency medical services and volunteers faced in the process of implementing drive-through testing centers to offer lessons learned and direction to health-care professionals in other countries."],"journal":"Disaster Med Public Health Prep","authors":["Kim, Edward"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32295659","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1017/dmp.2020.104","keywords":["covid-19","israel","coronavirus","drive-through","screening"],"locations":["Israel","Tel Aviv","Jerusalem","Haifa","Israel"],"countries":["Israel"],"countries_codes":["ISR|Israel"],"topics":["Prevention"],"weight":1,"_version_":1666138493273767937,"score":104.67138}]}